{"id":"innohep-tinzaparin","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Heparin-induced thrombocytopenia (HIT)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tinzaparin is derived from unfractionated heparin through controlled enzymatic depolymerization, resulting in a mixture of polysaccharide chains with molecular weights between 5,600 and 7,500 Da. It potentiates the inhibition of coagulation factors by antithrombin III, with a higher anti-Xa to anti-IIa activity ratio compared to unfractionated heparin, providing more predictable pharmacokinetics and allowing subcutaneous administration.","oneSentence":"Tinzaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:08.751Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Venous thromboembolism prophylaxis in patients undergoing general or orthopedic surgery"},{"name":"Treatment of acute deep vein thrombosis"},{"name":"Treatment of acute pulmonary embolism"},{"name":"Thromboembolism prophylaxis in acutely ill medical patients"}]},"trialDetails":[{"nctId":"NCT07140211","phase":"PHASE3","title":"Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis","status":"RECRUITING","sponsor":"Marc Blondon","startDate":"2025-10-15","conditions":"Venous Thromboembolism (VTE), Postpartum","enrollment":9200},{"nctId":"NCT05848713","phase":"PHASE3","title":"AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia","status":"RECRUITING","sponsor":"University of Manitoba","startDate":"2023-10-10","conditions":"Community-acquired Pneumonia","enrollment":4000},{"nctId":"NCT06381661","phase":"PHASE2","title":"Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05-01","conditions":"Sepsis","enrollment":2000},{"nctId":"NCT07361679","phase":"PHASE4","title":"LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention","status":"RECRUITING","sponsor":"Alexandra Hospital, Athens, Greece","startDate":"2023-01-18","conditions":"Preeclampsia Severe, Toxemia Of Pregnancy, Preeclampsia","enrollment":100},{"nctId":"NCT06370273","phase":"PHASE3","title":"Thromboprophylaxis in Lower Limb Immobilisation","status":"RECRUITING","sponsor":"Queen Mary University of London","startDate":"2024-11-12","conditions":"Thrombosis, Injury Leg","enrollment":10044},{"nctId":"NCT05255003","phase":"PHASE4","title":"STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis","status":"RECRUITING","sponsor":"Tzu-Fei Wang","startDate":"2022-08-29","conditions":"Cancer-associated Thrombosis, Thrombocytopenia","enrollment":50},{"nctId":"NCT07228663","phase":"PHASE3","title":"Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention","status":"NOT_YET_RECRUITING","sponsor":"McMaster University","startDate":"2025-12-01","conditions":"Hip Fracture Surgery, Cardiovascular Prevention, Venous Thromboembolism (VTE)","enrollment":100},{"nctId":"NCT05625932","phase":"PHASE3","title":"TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Galician Research Group on Digestive Tumors","startDate":"2023-03-02","conditions":"Colorectal Cancer Metastatic, Thromboembolism","enrollment":232},{"nctId":"NCT04741464","phase":"NA","title":"Effect of Tinzaparin on Inflammatory Biomarkers During the Acute Phase of Deep Vein Thrombosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2021-02-02","conditions":"Deep Vein Thrombosis, Inflammatory Response","enrollment":9},{"nctId":"NCT05735639","phase":"PHASE4","title":"THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2024-01-22","conditions":"Venous Thromboembolism, Varicose Veins","enrollment":6660},{"nctId":"NCT00277394","phase":"PHASE4","title":"Innohep® in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2005-12","conditions":"Deep Vein Thrombosis","enrollment":541},{"nctId":"NCT06494878","phase":"PHASE3","title":"The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity","status":"NOT_YET_RECRUITING","sponsor":"University of Calgary","startDate":"2025-04","conditions":"Venous Thromboembolism, Postpartum Period, Aspirin","enrollment":8805},{"nctId":"NCT05058924","phase":"NA","title":"Low Molecular Weight hEparin vs. Aspirin Post-partum","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2021-08-29","conditions":"Venous Thromboembolism","enrollment":30},{"nctId":"NCT05284552","phase":"PHASE2","title":"Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer","status":"RECRUITING","sponsor":"University Hospital, Linkoeping","startDate":"2022-07-12","conditions":"Epithelial Ovarian Cancer","enrollment":40},{"nctId":"NCT01130025","phase":"PHASE3","title":"Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2010-08","conditions":"Venous Thromboembolism","enrollment":900},{"nctId":"NCT05245877","phase":"PHASE4","title":"Pre- Vs. Postoperative Thromboprophylaxis in Pancreatic Surgery","status":"RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2022-08-17","conditions":"Pancreas Cancer, Pancreas Neoplasm, Surgery","enrollment":800},{"nctId":"NCT04731558","phase":"PHASE4","title":"Pre- Vs Postoperative Thromboprophylaxis for Liver Resection","status":"RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2021-02-10","conditions":"Liver Cancer, Surgery, Thrombosis, Deep Vein","enrollment":1012},{"nctId":"NCT04362085","phase":"PHASE3","title":"Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2020-05-11","conditions":"COVID-19","enrollment":465},{"nctId":"NCT04505774","phase":"PHASE4","title":"Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE","status":"COMPLETED","sponsor":"Matthew Neal MD","startDate":"2020-09-04","conditions":"Covid19","enrollment":3591},{"nctId":"NCT04979780","phase":"","title":"Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-07-20","conditions":"Treatment of Venous Thromboembolism in Cancer Patients, Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients","enrollment":3708},{"nctId":"NCT04508855","phase":"","title":"Management of Atrial Fibrillation in Patients With Cancer (MAFIC Study)","status":"WITHDRAWN","sponsor":"AHEPA University Hospital","startDate":"2020-08-01","conditions":"Cancer, Atrial Fibrillation","enrollment":""},{"nctId":"NCT04483960","phase":"PHASE3","title":"Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-07-28","conditions":"SARS-CoV-2 Infection (COVID-19)","enrollment":2200},{"nctId":"NCT04794569","phase":"PHASE4","title":"Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome","status":"TERMINATED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2021-11-15","conditions":"Deep Vein Thrombosis, Post Thrombotic Syndrome","enrollment":9},{"nctId":"NCT02580773","phase":"PHASE3","title":"Therapeutic Anticoagulation Strategy for Acute Chest Syndrome","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-12-16","conditions":"Anemia, Sickle Cell, Acute Chest Syndrome","enrollment":198},{"nctId":"NCT03614741","phase":"PHASE4","title":"Efficacy, Safety and Pharmacokinetics of Tinzaparin During Slow Low Efficient Daily Dialysis in Intensive Care Patients","status":"UNKNOWN","sponsor":"Tampere University Hospital","startDate":"2018-12-03","conditions":"Acute Kidney Injury, Renal Replacement Therapy, Anticoagulants","enrollment":60},{"nctId":"NCT06020560","phase":"PHASE4","title":"Study of Low Molecular Weight Heparins","status":"UNKNOWN","sponsor":"Herlev Hospital","startDate":"2023-03-23","conditions":"Anticoagulant, Venous Thromboembolism, Prophylaxis","enrollment":65000},{"nctId":"NCT04373707","phase":"PHASE4","title":"Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2020-05-13","conditions":"COVID, Thrombosis, Pulmonary Embolism","enrollment":1000},{"nctId":"NCT04593654","phase":"","title":"Dosing of Thromboprophylaxis and Mortality in Critically Ill COVID-19 Patients","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2020-03-01","conditions":"Covid19, Thromboembolism","enrollment":257},{"nctId":"NCT03178864","phase":"PHASE2","title":"Study of Rivaroxaban for CeREbral Venous Thrombosis","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2019-03-12","conditions":"Cerebral Venous Thrombosis","enrollment":55},{"nctId":"NCT03090880","phase":"PHASE3","title":"Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-09-14","conditions":"Venous Thromboembolism, Lung Neoplasm","enrollment":59},{"nctId":"NCT04730856","phase":"NA","title":"Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 Pneumonia (PROTHROMCOVID)","status":"COMPLETED","sponsor":"Hospital Universitario Infanta Leonor","startDate":"2021-02-01","conditions":"Covid19, Thrombosis","enrollment":311},{"nctId":"NCT04808882","phase":"PHASE2","title":"ANTIcoagulation in Severe COVID-19 Patients","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-04-14","conditions":"Severe COVID-19 Pneumonia","enrollment":353},{"nctId":"NCT01828697","phase":"PHASE4","title":"Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2013-04-24","conditions":"Deep Venous Thrombosis, Pulmonary Embolism","enrollment":1110},{"nctId":"NCT05178628","phase":"PHASE3","title":"The Impact of Thromboprophylaxis on Progression Free Survival of Patients With Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Michalis Karamouzis","startDate":"2022-02-10","conditions":"Pancreatic Cancer, Thromboembolism","enrollment":450},{"nctId":"NCT05279391","phase":"NA","title":"Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19","status":"UNKNOWN","sponsor":"Democritus University of Thrace","startDate":"2020-10-25","conditions":"COVID-19 Severe Respiratory Failure","enrollment":150},{"nctId":"NCT04444700","phase":"PHASE3","title":"A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2020-07-04","conditions":"COVID, Coronavirus Infection, Severe Acute Respiratory Syndrome","enrollment":465},{"nctId":"NCT05036824","phase":"","title":"Intensive Dose Tinzaparin in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"University Hospital of Patras","startDate":"2021-10-01","conditions":"Covid19, Hospitalization","enrollment":300},{"nctId":"NCT04196309","phase":"PHASE4","title":"Effect of LOW-molecular-weight Heparin in Reducing Radial Artery Occlusion Rate After Transradial Coronary Catheterization","status":"COMPLETED","sponsor":"AHEPA University Hospital","startDate":"2017-05-25","conditions":"Arterial Occlusion","enrollment":60},{"nctId":"NCT04372589","phase":"PHASE2, PHASE3","title":"Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)","status":"COMPLETED","sponsor":"University of Manitoba","startDate":"2020-05-20","conditions":"COVID-19, Pneumonia","enrollment":1200},{"nctId":"NCT01455831","phase":"PHASE3","title":"Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2011-09","conditions":"Adenocarcinoma of the Colon","enrollment":616},{"nctId":"NCT02583191","phase":"PHASE3","title":"Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients","status":"TERMINATED","sponsor":"AIO-Studien-gGmbH","startDate":"2016-03-23","conditions":"Venous Thromboembolism, Cancer","enrollment":246},{"nctId":"NCT04412291","phase":"PHASE2","title":"A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study","status":"UNKNOWN","sponsor":"Karolinska University Hospital","startDate":"2020-06-11","conditions":"Covid-19","enrollment":120},{"nctId":"NCT04412304","phase":"","title":"Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2020-03-06","conditions":"Covid-19, Thromboembolic Events, Bleeding","enrollment":166},{"nctId":"NCT04344756","phase":"PHASE2","title":"Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-04-20","conditions":"COVID19 Pneumonia","enrollment":808},{"nctId":"NCT03100123","phase":"EARLY_PHASE1","title":"AntiPhospholipid Syndrome Low-molecular-weight Heparin Pregnancy Loss Evaluation: The Pilot Study","status":"TERMINATED","sponsor":"Ottawa Hospital Research Institute","startDate":"2017-11-06","conditions":"Antiphospholipid Syndrome in Pregnancy, Pregnancy Loss","enrollment":1},{"nctId":"NCT03099031","phase":"","title":"Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-05","conditions":"Venous Thromboembolism","enrollment":420},{"nctId":"NCT01727427","phase":"","title":"Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients","status":"COMPLETED","sponsor":"G. d'Annunzio University","startDate":"2012-11","conditions":"Unsuspected Pulmonary Embolism","enrollment":695},{"nctId":"NCT03240120","phase":"PHASE3","title":"A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2017-09-01","conditions":"Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism","enrollment":99},{"nctId":"NCT02719418","phase":"","title":"Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses","status":"COMPLETED","sponsor":"Maisonneuve-Rosemont Hospital","startDate":"2016-02-01","conditions":"Renal Insufficiency, Chronic, Deep Venous Thrombosis, Protection Against","enrollment":28},{"nctId":"NCT01817257","phase":"PHASE2","title":"Anticoagulation Length in Cancer Associated Thrombosis","status":"TERMINATED","sponsor":"Cardiff University","startDate":"2013-12","conditions":"Cancer, Thrombosis, Venous Thromboembolism","enrollment":2},{"nctId":"NCT03665376","phase":"NA","title":"Feasibility and Efficacy of Enhanced Recovery After Surgery (ERAS) on Length of Stay Among Laparotomy Patients at Mbarara Regional Referral Hospital","status":"COMPLETED","sponsor":"Mbarara University of Science and Technology","startDate":"2017-06-01","conditions":"Laparotomy","enrollment":33},{"nctId":"NCT00790335","phase":"PHASE3","title":"Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2009-11","conditions":"Deep Vein Thrombosis, Venous Thrombosis, Postphlebitic Syndrome","enrollment":692},{"nctId":"NCT00225108","phase":"PHASE2, PHASE3","title":"The STOP CLOT Pilot Study: Study of Low Molecular Weight Heparin in High Risk Cesarean Section","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2002-07","conditions":"Deep Vein Thrombosis","enrollment":30},{"nctId":"NCT00407641","phase":"PHASE4","title":"Effects of Tinzaparin on Cardio-vascular Outcomes and on Blood Lipids in Diabetic Patients on Chronic Hemodialysis","status":"WITHDRAWN","sponsor":"Anemia Working Group Romania","startDate":"2009-03","conditions":"Diabetes Mellitus, Hemodialysis","enrollment":""},{"nctId":"NCT03230162","phase":"PHASE3","title":"Sildenafil Versus Low Molecular Weight Heparin in Fetal Growth Restriction Treatment","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2017-06-01","conditions":"Fetal Growth Abnormality, Fetal Growth Restriction","enrollment":100},{"nctId":"NCT00981903","phase":"PHASE2","title":"Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2005-07","conditions":"Venous Thromboembolism, Cancer","enrollment":131},{"nctId":"NCT02260414","phase":"PHASE2","title":"Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2015-04-14","conditions":"Lymphoma, Multiple Myeloma","enrollment":19},{"nctId":"NCT01930396","phase":"PHASE4","title":"Use of Tinzaparin for Anticoagulation in Hemodialysis","status":"COMPLETED","sponsor":"Christine Ribic","startDate":"2013-09","conditions":"Kidney Failure, Chronic","enrollment":191},{"nctId":"NCT00475098","phase":"PHASE3","title":"Effect of Low Molecular Weight Heparin: Tinzaparin in Lung Tumours (TILT)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2007-06","conditions":"Lung Cancer, Non Small Cell Lung Cancer","enrollment":553},{"nctId":"NCT01390051","phase":"PHASE4","title":"Can Low Molecular Weight Heparin During Pregnancy With Intrauterine Growth Restriction Increase Birth Weight?","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2011-07","conditions":"Fetal Growth Retardation","enrollment":50},{"nctId":"NCT00186745","phase":"NA","title":"Use of Low Molecular Weight Heparin (Tinzaparin) to Treat Blood Clots in Patients With Kidney Failure","status":"TERMINATED","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2005-03","conditions":"Venous Thrombosis, Pulmonary Embolism","enrollment":148},{"nctId":"NCT02091479","phase":"PHASE3","title":"Early Versus Late Resumption of Anticoagulation in Patients With Both High Thrombosis Risk and Major HEmoRrhage","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2013-01","conditions":"Major hæmorrhage","enrollment":14},{"nctId":"NCT00135863","phase":"NA","title":"MesoHep II: Intraperitoneal Low Molecular Weight Heparin in Peritoneal Dialysis","status":"TERMINATED","sponsor":"Ribe County Hospital","startDate":"2004-05","conditions":"Inflammation, Nutrition, Peritoneal Dialysis","enrollment":36},{"nctId":"NCT00238667","phase":"PHASE3","title":"To Determine the Feasibility of a Clinical Trial Comparing Anticoagulants Versus Antiplatelets in the Acute Treatment of Patients With Cervical Artery Dissection","status":"COMPLETED","sponsor":"St George's, University of London","startDate":"2005-11","conditions":"Cervical Artery Dissection, Carotid Artery Dissection, Vertebral Artery Dissection","enrollment":250},{"nctId":"NCT01064362","phase":"","title":"Hemorrhage Risk Prescribed Arixtra","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-01","conditions":"Thrombosis, Venous","enrollment":13442},{"nctId":"NCT01164046","phase":"PHASE3","title":"Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism","status":"TERMINATED","sponsor":"University Medical Center Groningen","startDate":"2010-08","conditions":"Venous Thromboembolism, Neoplasms","enrollment":56},{"nctId":"NCT00967148","phase":"NA","title":"Thromboprophylaxis for Patients Undergoing Surgical Resection for Colon Cancer","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2009-06","conditions":"Deep Vein Thrombosis, Pulmonary Embolism, Cancer","enrollment":18},{"nctId":"NCT00260988","phase":"PHASE2, PHASE3","title":"A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2003-10","conditions":"Thromboembolism, Hemodialysis","enrollment":29},{"nctId":"NCT01661439","phase":"","title":"Preconceptional Thromboprophylaxis in Recurrent PREGNANCY LOSSES Caused by Antiphospholipid Syndrome","status":"UNKNOWN","sponsor":"Woman's Health University Hospital, Egypt","startDate":"2012-03","conditions":"Recurrent Pregnancy Losses, Positive Anti Phospholipid Syndrome","enrollment":316},{"nctId":"NCT00293501","phase":"PHASE1, PHASE2","title":"Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery","status":"UNKNOWN","sponsor":"University of Vermont","startDate":"2005-12","conditions":"Kidney Cancer","enrollment":35},{"nctId":"NCT00851864","phase":"PHASE4","title":"Safety and Efficacy of Therapeutic Anticoagulation With Tinzaparin During Pregnancy Via Weight-based Dosing","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2007-10","conditions":"Venous Thromboembolism","enrollment":13},{"nctId":"NCT00061373","phase":"PHASE2","title":"Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2003-05","conditions":"Ischemic Stroke","enrollment":18},{"nctId":"NCT00629447","phase":"NA","title":"Innohep for Prophylaxis of Venous Thromboembolism in Brain Tumor Patients","status":"COMPLETED","sponsor":"Duke University","startDate":"2004-02","conditions":"Primary Brain Tumor","enrollment":40},{"nctId":"NCT01321788","phase":"","title":"Venous Thromboembolism Prophylaxis Post Cesarean Section","status":"UNKNOWN","sponsor":"King Saud University","startDate":"2011-01","conditions":"Bleeding, Venous Thromboembolism","enrollment":300},{"nctId":"NCT01357941","phase":"","title":"Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)","status":"UNKNOWN","sponsor":"Hamilton Health Sciences Corporation","startDate":"2011-09","conditions":"Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism","enrollment":203},{"nctId":"NCT00711308","phase":"PHASE4","title":"Tinzaparin in the Treatment of the Acute Pulmonary Embolism","status":"COMPLETED","sponsor":"Complejo Hospitalario Xeral-Calde","startDate":"2005-04","conditions":"Acute Pulmonary Embolism","enrollment":102},{"nctId":"NCT00689520","phase":"PHASE4","title":"Long-Term Low-Molecular-Weight Heparin Versus Oral Anticoagulants in Deep Venous Thrombosis","status":"COMPLETED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2002-01","conditions":"Venous Thromboembolism","enrollment":241},{"nctId":"NCT00628576","phase":"PHASE3","title":"Evaluation of Long-Term Sequelae After Thrombophlebitis, i.e. Deep Venous Thrombosis of the Lower Extremities","status":"COMPLETED","sponsor":"Aalborg University Hospital","startDate":"1993-10","conditions":"Deep Venous Thrombosis","enrollment":99},{"nctId":"NCT00203580","phase":"PHASE4","title":"Trial of the Effect of Low-Molecular-Weight Heparin (LMWH) Versus Warfarin on Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (DVT) (Main LITE Study)","status":"COMPLETED","sponsor":"University of Calgary","startDate":"1994-12","conditions":"Thrombosis, Thromboembolism, Venous Thrombosis","enrollment":910},{"nctId":"NCT00203658","phase":"PHASE4","title":"Assessment of Long-Term Out-of-Hospital Treatment of Patients With Proximal Deep Vein Thrombosis (DVT) Using Low-Molecular-Weight Heparin (LMWH) Versus LMWH Followed by Warfarin","status":"COMPLETED","sponsor":"University of Calgary","startDate":"1997-04","conditions":"Thrombosis, Thromboembolism, Venous Thrombosis","enrollment":400}],"_emaApprovals":[],"_faersSignals":[{"count":12,"reaction":"INCORRECT DRUG ADMINISTRATION DURATION"},{"count":11,"reaction":"OFF LABEL USE"},{"count":9,"reaction":"MATERNAL EXPOSURE DURING PREGNANCY"},{"count":8,"reaction":"EXPOSURE DURING PREGNANCY"},{"count":8,"reaction":"PULMONARY EMBOLISM"},{"count":7,"reaction":"DEEP VEIN THROMBOSIS"},{"count":5,"reaction":"CAESAREAN SECTION"},{"count":4,"reaction":"ABDOMINAL PAIN"},{"count":4,"reaction":"ANAEMIA"},{"count":4,"reaction":"ASCITES"}],"_approvalHistory":[],"publicationCount":516,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Innohep"],"phase":"marketed","status":"active","brandName":"Innohep (tinzaparin)","genericName":"Innohep (tinzaparin)","companyName":"Ottawa Hospital Research Institute","companyId":"ottawa-hospital-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tinzaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin. Used for Venous thromboembolism prophylaxis in patients undergoing general or orthopedic surgery, Treatment of acute deep vein thrombosis, Treatment of acute pulmonary embolism.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}